Gapping up
In reaction to strong earnings/guidance:
- CMBM +26.7% (raises guidance), SMPL +9.2%, LMNX +9.2% (guidance), GNMK +7.5% (guides Q2 revs above consensus), AA +4.2% (better than expected pre-announcement), SGH +2.8%
M&A news:
- NGHC +65.7% (to be acquired by Allstate (ALL) for $34.50 per share)
- SYNA +5.9% (to acquire Broadcom's (AVGO) wireless IoT connectivity unit for $250 mln in cash)
- DOCU +4.4% (acquires Liveoak Technologies for $38 mln in stock)
- KKR +2.8% (to acquire Global Atlantic Financial Group Limited)
Other news:
- NNVC +48.8% (reports that safety and tolerability of anti-Coronavirus drug candidates observed in an animal model further advances NanoViricides' SARS-CoV-2 therapeutics program)
- VBIV +21.1% (extends momentum from +21% move on Tues)
- CNCE +12.1% (receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata)
- FTI +11% (signs contract with Assiut National Oil)
- BIIB +7.3% (Biogen and Eisai Co. Ltd complete the submission of a Biologics License Application to the FDA for the approval of aducanumab)
- ABEO +6.8% (restarts patient enrollment in its Phase 3 VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa)
- CLNE +5.4% (partners with CVX on Adopt-a-Port)
- VVV +3.7% (provides preliminary June performance results)
- VFF +3.5% (executed a definitive agreement with DutchCanGrow to become one of six equal shareholders in DCG owning just under 16% each, with a seventh shareholder owning 5%)
- CORR +3.3% (says it's actively evaluating opportunities to deploy cash)
- NXTC +2.2% (announces the initiation of a Phase 1/2 clinical trial for NC410)
- BCLI +2.2% (to host webinar discussing NurOwn Phase 2 Alzheimer's Disease Program today at 8:15am ET)
- SCM +1.1% (provides Q2 update)
Analyst comments:
- NKLA +7.4% (upgraded to Overweight from Neutral at JP Morgan)
- BTAI +3.5% (target raised to $120 at H.C. Wainwright)
- HRI +3% (upgraded to Buy from Neutral at BofA Securities)
- KSS +2.8% (upgraded to Buy from Neutral at BofA Securities)
- DEO +2.4% (upgraded to Buy from Neutral at Bryan Garnier)
- CAT +1.1% (upgraded to Neutral from Underperform at BofA Securities)
- RIO +0.9% (upgraded to Sector Perform from Underperform at RBC Capital Mkts)